Nigel H Greig

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3847583/publications.pdf

Version: 2024-02-01

258	20,228	9254	13365
papers	citations	74 h-index	130 g-index

269	269	269	20977
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mitophagy inhibits amyloid-Î² and tau pathology and reverses cognitive deficits in models of Alzheimerâ€™s disease. Nature Neuroscience, 2019, 22, 401-412.	7.1	1,008
2	Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer Â-amyloid peptide in rodent. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17213-17218.	3.3	629
3	Mitophagy and Alzheimerâ€™s Disease: Cellular and Molecular Mechanisms. Trends in Neurosciences, 2017, 40, 151-166.	4.2	553
4	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	6.3	527
5	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1285-1290.	3.3	483
6	An Iron-responsive Element Type II in the 5â€²-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript. Journal of Biological Chemistry, 2002, 277, 45518-45528.	1.6	474
7	Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function. Cell Metabolism, 2016, 24, 332-340.	7.2	375
8	Butyrylcholinesterase: An Important New Target in Alzheimer's Disease Therapy. International Psychogeriatrics, 2002, 14, 77-91.	0.6	351
9	Drug discovery and development: Role of basic biological research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 651-657.	1.8	330
10	Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 881-888.	1.3	318
11	A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. Journal of Neurochemistry, 2001, 77, 220-228.	2.1	316
12	Glucagon-like peptide-1 decreases endogenous amyloid-Î² peptide (AÎ²) levels and protects hippocampal neurons from death induced by AÎ² and iron. Journal of Neuroscience Research, 2003, 72, 603-612.	1.3	309
13	Cholinesterases: Roles in the Brain During Health and Disease. Current Alzheimer Research, 2005, 2, 307-318.	0.7	303
14	N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimerâ€™s Disease, Vascular Dementia and Parkinsonâ€™s Disease. Current Alzheimer Research, 2012, 9, 746-758.	0.7	277
15	GLP-1 Receptor Stimulation Reduces Amyloid-Î² Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 1205-1219.	1.2	273
16	Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. Endocrinology, 2000, 141, 1936-1941.	1.4	271
17	A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 958-966.	1.3	260
18	Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimerâ€™s Disease. Current Alzheimer Research, 2015, 12, 32-46.	0.7	255

#	Article	IF	Citations
19	TNF-Î± protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. Journal of Neuroinflammation, 2012, 9, 23.	3.1	224
20	Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1432-1439.	0.8	209
21	Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Diseaseâ€. Journal of Medicinal Chemistry, 1999, 42, 1855-1861.	2.9	207
22	Neuroprotective and neurotrophic actions of glucagonâ€like peptideâ€1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology, 2012, 166, 1586-1599.	2.7	200
23	p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Annals of Neurology, 2002, 52, 597-606.	2.8	198
24	A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease. Current Drug Targets, 2003, 4, 97-112.	1.0	198
25	Neuroinflammation in animal models of traumatic brain injury. Journal of Neuroscience Methods, 2016, 272, 38-49.	1.3	195
26	Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2011, 10, 391-403.	0.8	192
27	Phenserine and ring C hetero-analogues: Drug candidates for the treatment of Alzheimer's disease. Medicinal Research Reviews, 1995, 15, 3-31.	5.0	188
28	Current drug targets for Alzheimer's disease treatment. Drug Development Research, 2002, 56, 267-281.	1.4	181
29	Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease. NeuroMolecular Medicine, 2002, 1, 1-32.	1.8	181
30	Tumor necrosis factor-Î± synthesis inhibitor 3,6â€²-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimerâ€™s disease. Journal of Neuroinflammation, 2012, 9, 106.	3.1	179
31	TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Current Alzheimer Research, 2007, 4, 378-385.	0.7	178
32	Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. Journal of Neurochemistry, 2010, 112, 1316-1326.	2.1	170
33	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease. JAMA Neurology, 2019, 76, 420.	4.5	169
34	Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Experimental Neurology, 2007, 203, 293-301.	2.0	166
35	Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease. Diabetes, 2009, 58, 318-328.	0.3	160
36	Protein Misfolding and Aggregation in Alzheimerâ€™s Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1280-1293.	0.8	138

#	Article	IF	Citations
37	Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. Journal of Neurochemistry, 2007, 100, 1421-1429.	2.1	133
38	TNF-Î± Induces Phenotypic Modulation in Cerebral Vascular Smooth Muscle Cells: Implications for Cerebral Aneurysm Pathology. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1564-1573.	2.4	133
39	Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-Î² peptide in mice. Behavioural Brain Research, 2011, 225, 222-229.	1.2	131
40	Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?. Journal of Alzheimer's Disease, 2008, 15, 303-325.	1.2	125
41	Optimizing drug delivery to brain tumors. Cancer Treatment Reviews, 1987, 14, 1-28.	3.4	124
42	Acetylcholinesterase and Its Inhibition in Alzheimer Disease. Clinical Neuropharmacology, 2004, 27, 141-149.	0.2	122
43	The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-Î² Peptide Levels in Cell Culture and Mice. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 386-396.	1.3	122
44	An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease. Current Alzheimer Research, 2005, 2, 281-290.	0.7	118
45	GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacology Biochemistry and Behavior, 1991, 40, 387-397.	1.3	113
46	Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease. Current Alzheimer Research, 2005, 2, 377-385.	0.7	113
47	Enhancing the GLPâ€1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. Journal of Neurochemistry, 2010, 113, 1621-1631.	2.1	111
48	A New Treatment Strategy for Parkinson's Disease through the Gutâ€“Brain Axis. Cell Transplantation, 2017, 26, 1560-1571.	1.2	111
49	A Synopsis on the Role of Tyrosine Hydroxylase in Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2012, 11, 395-409.	0.8	111
50	miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy. Journal of Alzheimer's Disease, 2015, 48, 563-580.	1.2	107
51	Transiently lowering tumor necrosis factor-Î± synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. Journal of Neuroinflammation, 2015, 12, 45.	3.1	107
52	Novel p53 Inactivators with Neuroprotective Action:Â Syntheses and Pharmacological Evaluation of 2-Imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-Imino-2,3,4,5,6,7-hexahydrobenzoxazole DerivativesâŠ¥. Journal of Medicinal Chemistry, 2002, 45, 5090-5097.	2.9	104
53	Critical role of TNF-Î± in cerebral aneurysm formation and progression to rupture. Journal of Neuroinflammation, 2014, 11, 77.	3.1	103
54	The glucagon-like peptides: a double-edged therapeutic sword?. Trends in Pharmacological Sciences, 2003, 24, 377-383.	4.0	102

#	Article	IF	Citations
55	A New Alzheimers Disease Interventive Strategy: GLP-1. Current Drug Targets, 2004, 5, 565-571.	1.0	102
56	The KATP Channel Activator Diazoxide Ameliorates Amyloid-Î² and Tau Pathologies and Improves Memory in the 3xTgAD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 443-457.	1.2	101
57	Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e32008.	1.1	101
58	Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. Endocrinology, 2000, 141, 1936-1941.	1.4	99
59	Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes. Diabetes Care, 2003, 26, 2835-2841.	4.3	97
60	Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemotherapy and Pharmacology, 1990, 26, 263-268.	1.1	92
61	New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-Â Inhibitors, and GLP-1 Receptor Agonists. Annals of the New York Academy of Sciences, 2004, 1035, 290-315.	1.8	91
62	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Frontiers in Cell and Developmental Biology, 2019, 7, 313.	1.8	91
63	The Role of microRNAs in Alzheimerâ€™s Disease and Their Therapeutic Potentials. Genes, 2018, 9, 174.	1.0	90
64	Apoptotic and behavioral sequelae of mild brain trauma in mice. Journal of Neuroscience Research, 2007, 85, 805-815.	1.3	88
65	Methyl Analogues of the Experimental Alzheimer Drug Phenserine:â€‰ Synthesis and Structure/Activity Relationships for Acetyl- and Butyrylcholinesterase Inhibitory Action. Journal of Medicinal Chemistry, 2001, 44, 4062-4071.	2.9	87
66	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12506-12511.	3.3	87
67	Tumor necrosis factorâ€Î± synthesis inhibitor, 3,6â€²â€dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. Journal of Neurochemistry, 2011, 118, 1032-1042.	2.1	87
68	The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. Journal of Alzheimer's Disease, 2002, 4, 487-496.	1.2	85
69	Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age, 2013, 35, 1621-1636.	3.0	83
70	Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Experimental Neurology, 2013, 239, 170-182.	2.0	80
71	Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain, 2017, 140, 1420-1436.	3.7	80
72	Early intervention with a small molecule inhibitor for tumor nefosis factor-Î± prevents cognitive deficits in a triple transgenic mouse model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2012, 9, 99.	3.1	79

#	Article	IF	Citations
73	Thiothalidomides:Â Novel Isosteric Analogues of Thalidomide with Enhanced TNF-Î± Inhibitory Activityâ€. Journal of Medicinal Chemistry, 2003, 46, 5222-5229.	2.9	78
74	Extension of Lifespan in C. elegans by Naphthoquinones That Act through Stress Hormesis Mechanisms. PLoS ONE, 2011, 6, e21922.	1.1	76
75	Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. Journal of Neurochemistry, 2015, 135, 1203-1217.	2.1	76
76	Physiological and Pathological Role of Alpha-synuclein in Parkinsonâ€™s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. International Journal of Molecular Sciences, 2009, 10, 1226-1260.	1.8	75
77	Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. Neurobiology of Disease, 2013, 54, 1-11.	2.1	75
78	A Pilot Study of Exenatide Actions in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 741-752.	0.7	75
79	Inhibition of Human Acetyl- and Butyrylcholinesterase by Novel Carbamates of (â^')- and (+)-Tetrahydrofurobenzofuran and Methanobenzodioxepine. Journal of Medicinal Chemistry, 2006, 49, 2174-2185.	2.9	74
80	Exendin-4 decreases amphetamine-induced locomotor activity. Physiology and Behavior, 2012, 106, 574-578.	1.0	74
81	Lessons from a BACE1 inhibitor trial: Offâ€site but not off base. Alzheimer's and Dementia, 2014, 10, S411-9.	0.4	69
82	p53 is Present in Synapses Where it Mediates Mitochondrial Dysfunction and Synaptic Degeneration in Response to DNA Damage, and Oxidative and Excitotoxic Insults. NeuroMolecular Medicine, 2003, 3, 159-172.	1.8	67
83	A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis. Current Alzheimer Research, 2006, 3, 81-90.	0.7	67
84	Cognitive Impairments Accompanying Rodent Mild Traumatic Brain Injury Involve p53-Dependent Neuronal Cell Death and Are Ameliorated by the Tetrahydrobenzothiazole PFT-Î±. PLoS ONE, 2013, 8, e79837.	1.1	67
85	Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-Î² peptide and Ï„ levels: target engagement, tolerability and pharmacokinetics in humans. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 894-902.	0.9	66
86	Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitorsâ€. Journal of Medicinal Chemistry, 2005, 48, 1919-1929.	2.9	65
87	Alzheimers Disease Drug Development in 2008 and Beyond: Problems and Opportunities. Current Alzheimer Research, 2008, 5, 346-357.	0.7	65
88	Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 682-692.	1.3	65
89	Rodent models of memory dysfunction in Alzheimer's disease and normal aging: Moving beyond the cholinergic hypothesis. Life Sciences, 1994, 55, 2037-2049.	2.0	64
90	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12703-12708.	3.3	64

#	Article	IF	Citations
91	Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. , 2014, 10, S62-S75.		64
92	Phenserine Efficacy in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1201-1208.	1.2	62
93	3,6â€²â€Dithiothalidomide, a new TNFâ€Î± synthesis inhibitor, attenuates the effect of AÎ²‹sub›1â€“42‹/sub› intracerebroventricular injection on hippocampal neurogenesis and memory deficit. Journal of Neurochemistry, 2012, 122, 1181-1192.	2.1	61
94	Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine. Neurochemical Research, 2008, 33, 745-753.	1.6	60
95	Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine. Biochemical Pharmacology, 2000, 60, 561-570.	2.0	59
96	Targets for AD treatment: conflicting messages from Î³-secretase inhibitors. Journal of Neurochemistry, 2011, 117, 359-374.	2.1	59
97	Total Syntheses and Anticholinesterase Activities of (3aS)-N(8)-Norphysostigmine, (3aS)-N(8)-Norphenserine, Their Antipodal Isomers, and OtherN(8)-Substituted Analoguesâ€. Journal of Medicinal Chemistry, 1997, 40, 2895-2901.	2.9	58
98	Neuronal Cellular Responses to Extremely Low Frequency Electromagnetic Field Exposure: Implications Regarding Oxidative Stress and Neurodegeneration. PLoS ONE, 2014, 9, e104973.	1.1	58
99	Rivastigmine Lowers AÎ² and Increases sAPPÎ± Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons. PLoS ONE, 2011, 6, e21954.	1.1	58
100	Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. Journal of Neural Transmission, 2008, 115, 889-898.	1.4	57
101	Neuroprotective Mechanisms Mediated by CDK5 Inhibition. Current Pharmaceutical Design, 2016, 22, 527-534.	0.9	57
102	Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors. Current Drug Targets, 2004, 5, 517-528.	1.0	57
103	Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. Current Alzheimer Research, 2017, 14, 1164-1181.	0.7	57
104	miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease. Medicinal Chemistry, 2016, 12, 217-225.	0.7	57
105	The alpha-synuclein 5â€²untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. Journal of Neural Transmission, 2011, 118, 493-507.	1.4	56
106	Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats. PLoS ONE, 2013, 8, e82016.	1.1	56
107	Neuroinflammation and ER-stress are key mechanisms of acute bilirubin toxicity and hearing loss in a mouse model. PLoS ONE, 2018, 13, e0201022.	1.1	56
108	The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regulatory Peptides, 2003, 114, 153-158.	1.9	54

#	Article	IF	Citations
109	Lost in Translation: Neuropsychiatric Drug Development. Science Translational Medicine, 2010, 2, 61rv6.	5.8	54
110	A new roadmap for drug development for Alzheimer's disease. Nature Reviews Drug Discovery, 2014, 13, 156-156.	21.5	54
111	Traumatic brain injury increases plasma astrocyteâ€derived exosome levels of neurotoxic complement proteins. FASEB Journal, 2020, 34, 3359-3366.	0.2	54
112	Tight binding dopamine reuptake inhibitors as cocaine antagonists. FEBS Letters, 1989, 257, 341-344.	1.3	53
113	Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepineâ‡. Journal of Medicinal Chemistry, 2005, 48, 986-994.	2.9	53
114	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. Frontiers in Psychiatry, 2021, 12, 536257.	1.3	53
115	Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Current Pharmaceutical Design, 2016, 22, 4360-4373.	0.9	53
116	Neuroprotective effects of pifithrin-Î± against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. Scientific Reports, 2018, 8, 2368.	1.6	52
117	Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimer's and Dementia, 2022, 18, 2327-2340.	0.4	51
118	Neurotrophic and Neuroprotective Actions of (â^')- and (+)-Phenserine, Candidate Drugs for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e54887.	1.1	50
119	Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Experimental Neurology, 2004, 190, 133-144.	2.0	49
120	Synergistic effect of apolipoprotein E Îµ4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and Genomics, 2008, 18, 289-298.	0.7	49
121	Blast traumatic brain injuryâ€“induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagonâ€like peptideâ€1 receptor agonist, exendinâ€4. Alzheimer's and Dementia, 2016, 12, 34-48.	0.4	48
122	Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. NeuroReport, 1995, 6, 481-484.	0.6	46
123	Presence of a â€œCAGA boxâ€•in the APP gene unique to amyloid plaqueâ€forming species and absent in all APLP â€1/2 genes: implications in Alzheimer's disease. FASEB Journal, 2004, 18, 1288-1290.	0.2	45
124	Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimerâ€™s Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway. Current Alzheimer Research, 2014, 11, 608-622.	0.7	45
125	Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 10722.	1.6	44
126	Immunomodulatory drugs alleviate <scp>l</scp>â€dopaâ€induced dyskinesia in a rat model of Parkinson's disease. Movement Disorders, 2019, 34, 1818-1830.	2.2	44

#	Article	IF	Citations
127	Rivastigmine modifies the Î±-secretase pathway and potentially early Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 47.	2.4	44
128	In vivoscreening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget, 2016, 7, 33237-33245.	0.8	44
129	Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by a Novel Derivative of Physostigmine: Phenserine. Biochemical and Biophysical Research Communications, 1998, 248, 180-185.	1.0	43
130	Roles of p75NTR, Long-Term Depression, and Cholinergic Transmission in Anxiety and Acute Stress Coping. Biological Psychiatry, 2012, 71, 75-83.	0.7	43
131	Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Experimental Neurology, 2015, 273, 151-160.	2.0	43
132	A cellular model of inflammation for identifying TNF-Î± synthesis inhibitors. Journal of Neuroscience Methods, 2009, 183, 182-187.	1.3	42
133	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2017, 9, 77.	1.7	42
134	Neuronal Enriched Extracellular Vesicle Proteins as Biomarkers for Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 975-987.	1.7	42
135	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. Journal of Alzheimer's Disease, 2006, 10, 43-51.	1.2	40
136	Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects. Current Alzheimer Research, 2005, 2, 483-492.	0.7	39
137	Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-Î² Peptide. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 855-862.	1.3	39
138	Alzheimerâ€™s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. CNS and Neurological Disorders - Drug Targets, 2012, 11, 482-489.	0.8	39
139	Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. Journal of Neuroinflammation, 2016, 13, 168.	3.1	39
140	Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. Scientific Reports, 2017, 7, 3735.	1.6	39
141	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. Current Alzheimer Research, 2017, 14, 1190-1197.	0.7	39
142	Physovenines: Efficient Synthesis of (?)- and (+)-Physovenine and Synthesis of Carbarnate Analogues of (?)-Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. Helvetica Chimica Acta, 1991, 74, 761-766.	1.0	38
143	Cognitive Enhancement.. Annals of the New York Academy of Sciences, 1996, 786, 348-361.	1.8	38
144	Cholinesterase Inhibitors Improve Both Memory and Complex Learning in Aged Beagle Dogs. Journal of Alzheimer's Disease, 2011, 26, 143-155.	1.2	38

#	Article	IF	Citations
145	3,6â€²â€dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. Journal of Neuroscience Research, 2013, 91, 671-680.	1.3	38
146	Dopaminergic neuronâ€specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model. Journal of Neurochemistry, 2016, 138, 746-757.	2.1	38
147	Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimerâ€™s disease. Journal of Chromatography A, 2009, 1216, 2730-2738.	1.8	37
148	The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5^{â€²}Untranslated-Region-Directed Translation Blockers of the Parkinsonâ€™s Alpha Synuclein Expression. Parkinson's Disease, 2012, 2012, 1-13.	0.6	37
149	Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimerâ€™s Disease. Cells, 2021, 10, 993.	1.8	37
150	Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid-Î² Levels. PLoS ONE, 2013, 8, e58752.	1.1	36
151	Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. PLoS ONE, 2016, 11, e0156493.	1.1	36
152	Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 200-206.	1.1	35
153	Post-traumatic administration of the p53 inactivator pifithrin-Î± oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury. Neurobiology of Disease, 2016, 96, 216-226.	2.1	34
154	Novel GLP-1R/GIPR co-agonist â€œtwincretinâ€•is neuroprotective in cell and rodent models of mild traumatic brain injury. Experimental Neurology, 2017, 288, 176-186.	2.0	34
155	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinsonâ€™s disease. Expert Opinion on Investigational Drugs, 2020, 29, 595-602.	1.9	34
156	(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice. Neurobiology of Disease, 2019, 130, 104528.	2.1	33
157	The p53 inactivators pifithrin-Î¼ and pifithrin-Î± mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy. Experimental Neurology, 2020, 324, 113135.	2.0	33
158	Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiologiae Experimentalis, 2004, 64, 1-9.	0.4	33
159	Fire in the ashes: Can failed Alzheimer's disease drugs succeed with second chances?. Alzheimer's and Dementia, 2013, 9, 50-57.	0.4	32
160	New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors. Recent Patents on CNS Drug Discovery, 2013, 8, 123-141.	0.9	32
161	Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. Journal of Neurotrauma, 2016, 33, 2044-2054.	1.7	31
162	(â^')-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury. Brain Research, 2017, 1677, 118-128.	1.1	31

#	Article	IF	Citations
163	Syntheses and Anticholinesterase Activities of (3aS)-N,N8-Bisnorphenserine, (3aS)-N1,N8-Bisnorphysostigmine, Their Antipodal Isomers, and Other Potential Metabolites of Phenserine. Journal of Medicinal Chemistry, 1998, 41, 2371-2379.	2.9	30
164	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorganic and Medicinal Chemistry, 2010, 18, 4687-4693.	1.4	29
165	Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. Journal of Biomedical Science, 2017, 24, 71.	2.6	29
166	Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. Future Medicinal Chemistry, 2019, 11, 489-493.	1.1	29
167	Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in Cell and Developmental Biology, 2019, 7, 356.	1.8	29
168	Insertion of an N-Terminal 6-Aminohexanoic Acid after the 7 Amino Acid Position of Glucagon-Like Peptide-1 Produces a Long-Acting Hypoglycemic Agent. Endocrinology, 2001, 142, 4462-4468.	1.4	28
169	Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Biochemical Journal, 2009, 417, 213-222.	1.7	28
170	Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development. Journal of Neuroscience Methods, 2016, 272, 4-18.	1.3	28
171	Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?. Alzheimer's and Dementia, 2018, 14, 431-443.	0.4	28
172	Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. ACS Pharmacology and Translational Science, 2019, 2, 66-91.	2.5	28
173	Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis. Trends in Neurosciences, 2019, 42, 151-163.	4.2	27
174	Adiponectin as a Potential Therapeutic Target for Prostate Cancer. Current Pharmaceutical Design, 2017, 23, 4170-4179.	0.9	27
175	Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-Î± and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation. The Open Biochemistry Journal, 2011, 5, 37-44.	0.3	25
176	Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiology of Disease, 2019, 124, 439-453.	2.1	25
177	Pomalidomide Ameliorates H2O2-Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects. International Journal of Molecular Sciences, 2018, 19, 3252.	1.8	24
178	Linking Alzheimerâ€™s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation. CNS and Neurological Disorders - Drug Targets, 2014, 13, 338-346.	0.8	24
179	3,6â€™-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation. ELife, 2020, 9, .	2.8	24
180	Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Experimental Neurology, 2017, 288, 104-113.	2.0	23

#	Article	IF	Citations
181	Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 117-128.	1.1	23
182	Lethal weapon: amyloid Î²-peptide, role in the oxidative stress and neurodegeneration of Alzheimerâ€™s disease. Neurobiology of Aging, 2004, 25, 581-587.	1.5	22
183	Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. Biochemical Journal, 2012, 444, 269-277.	1.7	22
184	Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-Î± inhibitory activity. Bioorganic and Medicinal Chemistry, 2011, 19, 3965-3972.	1.4	21
185	Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6â€²-Dithiothalidomide on Traumatic Brain Injury. International Journal of Molecular Sciences, 2019, 20, 502.	1.8	21
186	Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury. ELife, 2020, 9, .	2.8	21
187	Transgenerational latent early-life associated regulation unites environment and genetics across generations. Epigenomics, 2016, 8, 373-387.	1.0	20
188	Syntheses of Tetrahydrofurobenzofurans and Dihydromethanobenzodioxepines from 5-Hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and Ring Expansion under Reductive Conditions on Treatment with Hydrides. Journal of Organic Chemistry, 2005, 70, 6171-6176.	1.7	19
189	Evidence of a Novel Mechanism for Partial Î³-Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid Î² Protein. PLoS ONE, 2014, 9, e91531.	1.1	19
190	Was Phenserine a Failure or Were Investigators Mislead by Methods?. Current Alzheimer Research, 2012, 9, 1174-1181.	0.7	18
191	Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development. Journal of Neuroscience Methods, 2016, 272, 69-76.	1.3	18
192	The metabolite GLPâ€1 (9â€36) is neuroprotective and antiâ€inflammatory in cellular models of neurodegeneration. Journal of Neurochemistry, 2021, 159, 867-886.	2.1	18
193	A New Regulatory Road-Map for Alzheimerâ€™s Disease Drug Development. Current Alzheimer Research, 2014, 11, 215-220.	0.7	18
194	Total Synthesis of Racemic and Optically Active Compounds Related to Physostigmine and Ring-C Heteroanalogues from 3-[2?-(dimethylamino)ethyl]2,3-dihydro-5-methoxy-1,3-dimethyl-1H-indo l-2-ol. Helvetica Chimica Acta, 1994, 77, 1412-1422.	1.0	17
195	Improved post-stroke spontaneous recovery by astrocytic extracellular vesicles. Molecular Therapy, 2022, 30, 798-815.	3.7	17
196	Inhibition of Caspase 3 and Caspase 9 Mediated Apoptosis: A Multimodal Therapeutic Target in Traumatic Brain Injury. Current Neuropharmacology, 2023, 21, 1001-1012.	1.4	17
197	In Vivo Biological Activity of Exendin (1â€“30). Endocrine, 2005, 27, 001-010.	2.2	16
198	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. Lancet Psychiatry,the, 2015, 2, 756-764.	3.7	16

#	Article	IF	Citations
199	Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. Scientific Reports, 2019, 9, 17208.	1.6	16
200	Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Experimental Neurology, 2020, 324, 113113.	2.0	16
201	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Frontiers in Neuroscience, 2021, 15, 656921.	1.4	16
202	PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 785.	1.4	15
203	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimerâ€™s Disease. Current Alzheimer Research, 2018, 15, 883-891.	0.7	15
204	Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. CNS and Neurological Disorders - Drug Targets, 2017, 16, 820-827.	0.8	15
205	Preclinical Investigation of the Topical Administration of Phenserine: Transdermal Flux, Cholinesterase Inhibition, and Cognitive Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 353-361.	1.3	14
206	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease. NeuroMolecular Medicine, 2007, 9, 157-168.	1.8	14
207	(-)-Phenserine Attenuates Soman-Induced Neuropathology. PLoS ONE, 2014, 9, e99818.	1.1	14
208	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-Î± and angiogenesis inhibitory activities. Bioorganic and Medicinal Chemistry, 2018, 26, 1547-1559.	1.4	14
209	Pomalidomide Reduces Ischemic Brain Injury in Rodents. Cell Transplantation, 2019, 28, 439-450.	1.2	14
210	N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. ACS Pharmacology and Translational Science, 2021, 4, 980-1000.	2.5	14
211	Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats. International Journal of Molecular Sciences, 2018, 19, 1153.	1.8	13
212	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 31.	1.7	13
213	Diphtheria toxin induced but not CSF1R inhibitor mediated microglia ablation model leads to the loss of CSF/ventricular spaces in vivo that is independent of cytokine upregulation. Journal of Neuroinflammation, 2022, 19, 3.	3.1	13
214	(â^')â€Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. CNS Neuroscience and Therapeutics, 2020, 26, 636-649.	1.9	12
215	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinsonâ€™s Disease. ACS Pharmacology and Translational Science, 2021, 4, 858-869.	2.5	12
216	Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development. Current Alzheimer Research, 2009, 6, 79-81.	0.7	11

#	Article	IF	Citations
217	(-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice. Cell Transplantation, 2019, 28, 1183-1196.	1.2	11
218	Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons. Neurotoxicity Research, 2019, 36, 347-356.	1.3	11
219	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. Molecules, 2020, 25, 5683.	1.7	11
220	Neurine, an acetylcholine autolysis product, elevates secreted amyloid-Î² protein precursor and amyloid-Î² peptide levels, and lowers neuronal cell viability in culture: A role in Alzheimer's disease?. Journal of Alzheimer's Disease, 2006, 10, 9-16.	1.2	10
221	Acetylcholinesterase inhibition ameliorates deficits in motivational drive. Behavioral and Brain Functions, 2012, 8, 15.	1.4	10
222	Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity. Neurotoxicity Research, 2017, 32, 218-230.	1.3	10
223	High Throughput Virtual Screening and Molecular Dynamics Simulation for Identifying a Putative Inhibitor of Bacterial CTX-M-15. Antibiotics, 2021, 10, 474.	1.5	10
224	3,6â€²-Dithiopomalidomide Ameliorates Hippocampal Neurodegeneration, Microgliosis and Astrogliosis and Improves Cognitive Behaviors in Rats with a Moderate Traumatic Brain Injury. International Journal of Molecular Sciences, 2021, 22, 8276.	1.8	10
225	Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. VirusDisease, 2018, 29, 419-433.	1.0	9
226	Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-Î² Pathology in Female Rhesus Macaques (Macaca Mulatta). Journal of Alzheimer's Disease, 2019, 68, 115-126.	1.2	9
227	Post-treatment with Posiphen Reduces Endoplasmic Reticulum Stress and Neurodegeneration in Stroke Brain. IScience, 2020, 23, 100866.	1.9	9
228	Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 129-135.	1.1	9
229	Reply to Dâ€™Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4820.	3.3	8
230	Age-related impairment of cerebral blood flow response to K_{ATP} channel opener in Alzheimerâ€™s disease mice with presenilin-1 mutation. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1579-1591.	2.4	8
231	nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse. Scientific Reports, 2021, 11, 9711.	1.6	8
232	Sequential combined Treatment of Pifithrin-Î± and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke. Cell Transplantation, 2018, 27, 607-621.	1.2	7
233	Thionation of Aminophthalimide Hindered Carbonyl Groups and Application to the Synthesis of 3,6â€²-Dithionated Pomalidomides. Synlett, 2021, 32, 917-922.	1.0	7
234	Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment. Current Medicinal Chemistry, 2022, 29, 5289-5314.	1.2	7

#	Article	IF	Citations
235	Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders. Journal of Biological Chemistry, 2017, 292, 20353.	1.6	6
236	Is insulin resistance the cause of fibromyalgia? A preliminary report. PLoS ONE, 2019, 14, e0216079.	1.1	6
237	Amyloidâ€Î² precursor protein synthesis inhibitors for Alzheimer's disease treatment. Annals of Neurology, 2014, 76, 629-630.	2.8	5
238	In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes. ACS Pharmacology and Translational Science, 2022, 5, 70-79.	2.5	5
239	Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease. Current Medicinal Chemistry, 2023, 30, 255-270.	1.2	5
240	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq0 0 0 rgBT /Overlock 10 515-517.	0.9	4
241	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq1 1 0.784314 rgBT /O 2016, 22, 2923-2925.	0.9	3
242	Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases. Current Pharmaceutical Design, 2017, 23, 1571-1574.	0.9	3
243	Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?. Neuropharmacology, 2018, 136, 159.	2.0	3
244	Can We Prevent Dementia and Not Prevent Neurons from Dying?. Journal of Alzheimer's Disease, 2019, 68, 489-492.	1.2	3
245	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease. NeuroMolecular Medicine, 2007, 9, 157-168.	1.8	3
246	Exploring N¹-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment. CNS and Neurological Disorders - Drug Targets, 2014, 13, 197-202.	0.8	3
247	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. Neurotherapeutics, 2022, 19, 305-324.	2.1	3
248	3,6â€²- and 1,6â€²-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. Pharmaceutics, 2022, 14, 950.	2.0	3
249	Dissociation Between the Potent Î²-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine. , 2008, , 445-462.		2
250	Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside) Tj ETQq0 0 0 rgBT /Overlock 10 2016, 22, 4337-4340.	0.9	1
251	Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives. Current Alzheimer Research, 2017, 14, 1138-1139.	0.7	1
252	Geriatric pharmacotherapy: Appraising new drugs for neurologic disorders in older patients. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 3-18.	1.0	1

#	Article	IF	Citations
253	P3â€061: CONSTITUTIVE IN VIVO OVEREXPRESSION OF MIR146A AND MIR200B INDEPENDENTLY MODULATES LEVELS OF ALZHEIMER'S DISEASE (AD)â€•RELATED PROTEINS IN THE MOUSE HIPPOCAMPUS AND CEREBRAL CORTEX. Alzheimer's and Dementia, 2018, 14, P1088.	0.4	0
254	P3â€053: (â€)â€PHENSERINE (PHEN) AND THE PREVENTION OF PREâ€PROGRAMMED CELL DEATH IN ALZHEIMER'S DISEASE (AD) AND MILD TRAUMATIC BRAIN INJURY (MTBI). Alzheimer's and Dementia, 2018, 14, P1083.	0.4	0
255	Neuronal Hyperexcitability Following mTBI. , 2019, , 67-81.		0
256	GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR6-4.	0.0	0
257	Inhibition of butyrylcholinesterase improves prepulse inhibition deficits and enhances M1 muscarinic acetylcholine receptor-mediated responses via ghrelin signaling in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-134.	0.0	0
258	Posiphen â€“ a new experimental drug to understand and mitigate age-related neurodegenerative disorders. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY54-3.	0.0	0